Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

3' V(D)J scRNASeq of splenic CD3+ cells from immunodeficient mice injected with progenitor T-cells generated from naïve, non-expanded or SR1-expanded human cord blood-derived CD34+ cells

ABSTRACT: 3' V(D)J scRNASeq of splenic CD3+ cells from immunodeficient mice injected with progenitor T-cells generated from naïve, non-expanded or SR1-expanded human cord blood-derived CD34+ cells

PROVIDER: PRJNA560657 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9992780.fastq.gz	Fastqsanger.gz
	SRR9992781.fastq.gz	Fastqsanger.gz
	SRR9992782.fastq.gz	Fastqsanger.gz
	SRR9992783.fastq.gz	Fastqsanger.gz
	SRR9992784.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

5' scRNAseq of splenic CD3+ cells from immunodeficient mice injected with progenitor T-cells generated from naïve, non-expanded or SR1-expanded human cord blood-derived CD34+ cells

Project description:We report the gene expression profile of single cell peripheral CD3+ cells from immunodeficient mice injected with human progenitor T-cells (proT-cells). ProT-cell subsets were generated in vitro using human umbilical cord blood-derived CD34+ cells that were either non-expanded (naive), or expanded in vitro with the hydrocarbon receptor antagonist, StemRegenin-1 (SR1).

2019-10-15 | GSE135927 | GEO

3' V(D)J scRNASeq of splenic CD3+ cells from immunodeficient mice injected with progenitor T-cells generated from naïve, non-expanded or SR1-expanded human cord blood-derived CD34+ cells

2019-10-15 | GSE135928 | GEO

scRNASeq of splenic CD3+ cells from immunodeficient mice injected with progenitor T-cells generated from naïve, non-expanded or SR1-expanded human cord blood-derived CD34+ cells

Project description:scRNASeq of splenic CD3+ cells from immunodeficient mice injected with progenitor T-cells generated from naïve, non-expanded or SR1-expanded human cord blood-derived CD34+ cells

| PRJNA560655 | ENA

5' scRNAseq of splenic CD3+ cells from immunodeficient mice injected with progenitor T-cells generated from naïve, non-expanded or SR1-expanded human cord blood-derived CD34+ cells

Project description:5' scRNAseq of splenic CD3+ cells from immunodeficient mice injected with progenitor T-cells generated from naïve, non-expanded or SR1-expanded human cord blood-derived CD34+ cells

| PRJNA560656 | ENA

scRNASeq of splenic CD3+ cells from immunodeficient mice injected with progenitor T-cells generated from naïve, non-expanded or SR1-expanded human cord blood-derived CD34+ cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-10-15 | GSE135929 | GEO

Bacillus subtilis strain:SR1 | isolate:SR1

Project description:Bacillus subtilis strain:SR1 | isolate:SR1 Genome sequencing and assembly

| PRJNA388844 | ENA

Nicotiana tabacum strain:SR1 | cultivar:SR1

Project description:Nicotiana tabacum strain:SR1 | cultivar:SR1 Transcriptome or Gene expression

| PRJNA271947 | ENA

Exponential expansion of CD34+ cells in response to StemRegenin-1 occurs with minimal changes in gene expression

Project description:Hematopoietic stem/progenitor cell transplantation (HSCT) is a well-established treatment option for hematological and other disorders. Umbilical cord blood (UCB) is a rich source of hematopoietic stem and progenitor cells (HSPCs). Cluster of Differentiation (CD)34 is commonly used as a cell surface marker to identify and isolate HSPCs. Transplantation using a single UCB unit may be associated with delayed hematopoietic reconstitution as it may not contain a sufficient number of HSPCs required for adult transplantation. One way of overcoming this limitation is through ex vivo expansion of UCB-derived HSPCs using the aryl hydrocarbon receptor (AhR) antagonist, StemRegenin-1 (SR1), which promotes the expansion of HSPCs. Our study investigated the effects of SR1 on the transcriptome of expanded CD34+ cells from UCB, and we also report on a comparison between the transcriptome profiles of 7-day expanded and non-expanded CD34+ cells. CD34+ HSPCs expanded with SR1 for 7 days displayed two significantly downregulated genes, cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1) and erythrocyte membrane protein band 4.1-like 3 (EPB41L3), when compared to controls (without SR1). Transcriptome analysis of CD34+ HSPCs expanded for 7 days using SR1 revealed that 391 genes were significantly upregulated, while 456 genes were significantly downregulated when compared to non-expanded CD34+ cells. In conclusion, though hundreds of genes were differentially expressed between SR1-expanded and non-expanded CD34+ HSPCs, only two genes were significantly downregulated in cells expanded for 7 days with SR1 versus control at the same time point (without SR1).

2024-09-25 | GSE146810 | GEO

Transcriptome data of CD34+ human cord blood-derived cell treated with UM171, SR1 or both

Project description:mRNA profiling of CD34+ human cord blood-derived cell treated with UM171, SR1 or both mRNA profiles of CD34+ human cord blood-derived cell treated with DMSO (control), SR1 [500nM], UM171 [35nM] or combination SR1 [500nM]+ UM171 [35nM] for 30min, 3hr, 12hr, 24hr, 48hr, 72hr were generated by deep sequencing

2014-10-21 | E-GEOD-57299 | biostudies-arrayexpress

Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells

Project description:Although practiced clinically for more than 40 years, the use of hematopoietic stem cell (HSC) transplants remains limited by the ability to expand these cells ex vivo. An unbiased screen with primary human HSCs identified a purine derivative, StemRegenin 1 (SR1), that promotes the ex vivo expansion of CD34+ cells. Culture of HSCs with SR1 led to a 50-fold increase in cells expressing CD34 and a 17-fold increase in cells that retain the ability to engraft immunodeficient mice. Mechanistic studies show that SR1 acts by antagonizing the aryl hydrocarbon receptor (AHR). The identification of SR1 and AHR modulation as a means to induce ex vivo HSC expansion should facilitate the clinical use of HSC therapy. LGC006, a less potent SR1 analog, was also examined. KEYWORDS: two compounds, multiple doses, one time point two compounds, multiple doses, one time point

2011-04-04 | E-GEOD-28359 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data